Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
142.44
+1.19 (0.84%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Neurocrine Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $207.29. The average 1-year stock price forecast is 45.53% higher than the current stock price, while the lowest is $164 (+15.14%) and the highest is $253 (+77.62%).
Price Target: $207.29 (+45.53%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 20 | 21 | 20 | 20 | 21 | 21 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 29 | 28 | 28 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Reiterates $214 | Buy | Reiterates | $214 | +50.24% | Oct 9, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $210 | Buy | Reiterates | $210 | +47.43% | Oct 9, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $187 | Buy | Maintains | $187 | +31.28% | Oct 9, 2026 |
| Guggenheim | Guggenheim | Buy Initiates $207 | Buy | Initiates | $207 | +45.32% | Oct 5, 2026 |
| Jefferies | Jefferies | Buy Maintains $220 | Buy | Maintains | $220 | +54.45% | Sep 29, 2026 |
Financial Forecast
Revenue This Year
3.90B
from 2.86B
Increased by 36.44%
Revenue Next Year
4.55B
from 3.90B
Increased by 16.61%
EPS This Year
10.21
from 6.39
Increased by 59.85%
EPS Next Year
11.88
from 10.21
Increased by 16.28%
EPS and Forward PE are based on non-GAAP adjusted numbers.